<DOC>
	<DOCNO>NCT00408655</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus , carboplatin , paclitaxel treat patient advance solid tumor . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving temsirolimus together chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Temsirolimus , Carboplatin , Paclitaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) recommend phase II dose temsirolimus , carboplatin , paclitaxel patient advance solid tumor . SECONDARY OBJECTIVES : I . Determine frequency severity toxic effect regimen patient . II . Document evidence objective antitumor activity regimen patient measurable disease . III . Determine pharmacokinetic profile carboplatin paclitaxel alone , temsirolimus alone , carboplatin , paclitaxel , temsirolimus combination patient . OUTLINE : This multicenter , open-label , dose-escalation study . Patients receive treatment either part A part B . PART A : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30-60 minute day 1 temsirolimus IV 30 minute day 8 15 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . PART B : Patients receive paclitaxel carboplatin part A . They also receive temsirolimus IV 30 minute day 1 8 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient part A B receive escalating dos temsirolimus , carboplatin , paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . The recommended phase II dose ( RPTD ) dose one dose level MTD . Once RPTD determine part A , patient enrol part B . An expanded cohort 10 patient endometrial ovarian cancer treat RPTD determine part B ( final RPTD ) . After completion study treatment , patient follow 4 week every 3 month thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Criteria : Histologically confirm solid tumor Measurable nonmeasurable disease : No serum tumor marker elevation evidence disease ; Patients ovarian endometrial cancer must measurable disease , define &gt; = 1 lesion &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan Advanced disease ; Refractory standard therapy OR standard therapy available Carboplatin paclitaxel consider reasonable therapeutic option No known brain metastasis ECOG performance status 01 Life expectancy &gt; = 12 week Absolute granulocyte count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) AST ALT = &lt; 3 time ULN ( 5 time ULN document liver metastasis ) Fasting serum cholesterol = &lt; 9.0 mmol/L Fasting triglycerides = &lt; 4.56 mmol/L Creatinine normal OR creatinine clearance &gt; = 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Accessible treatment follow No serious cardiovascular illness , include follow : myocardial infarction within past 6 month , congestive heart failure ( even medically control ) , unstable angina , active cardiomyopathy , cardiac arrhythmia , uncontrolled hypertension No preexist sensory motor neuropathy &gt; = grade 2 due previous chemotherapy ; Local regional neurological finding relate previous injury disease allow No hearing loss &gt; = grade 2 cause No history allergic reaction attribute compound similar chemical biological composition temsirolimus No serious illness medical condition would preclude study treatment include , limited , follow : History significant neurologic psychiatric disorder would impair ability obtain consent limit study compliance , Active uncontrolled infection nonhealing wound , OR ; At least 4 week since prior radiotherapy ( except lowdose , palliative radiotherapy ) recover At least 4 week since prior chemotherapy recover No 2 prior chemotherapy regimens Prior therapy carboplatin and/or paclitaxel allow provided patient persistent relate toxicity &gt; = grade 1 AND retreatment combination clinically indicate ( e.g. , secondline therapy ovarian cancer &gt; 6month treatmentfree interval ) At least 21 day since prior major surgery recover No prior mTOR inhibitor No concurrent prophylactic hematopoietic colonystimulating factor No concurrent anticancer therapy investigational agent Active peptic ulcer disease , Any medical condition might aggravate treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>